Octreotide treatment of patients with hepatocellular carcinoma – A retrospective single centre controlled study

Background and Aims: Treatment of patients with hepatocellular carcinoma (HCC) with octreotide gave conflicting results on influence on survival. We analyzed retrospectively the survival of our patient population treated with octreotide monotherapy and compared it to patients who received either TACE, multimodal therapy or palliative care. Methods: 95 patients with hepatocellular carcinoma (HCC) in BCLC stage A or B, who received either TACE, multimodal therapy, long-acting octreotide [Sandostatin LAR] or palliative care were reviewed for this retrospective study. Results: Survival rates of patients with BCLC st…